We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 24, 2022

Recombinant BCG Immunotherapy for BCG-Refractory Non–Muscle-Invasive Bladder Cancer

European Urology Oncology


Additional Info

European Urology Oncology
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14
Eur Urol Oncol 2022 Jan 07;[EPub Ahead of Print], CA Rentsch, GN Thalmann, I Lucca, M Kwiatkowski, GJ Wirth, RT Strebel, D Engeler, A Pedrazzini, C Hüttenbrink, W Schultze-Seemann, R Torpai, L Bubendorf, A Wicki, B Roth, P Bosshard, H Püschel, DT Boll, L Hefermehl, F Roghmann, M Gierth, K Ribi, S Schäfer, S Hayoz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading